CeQur is dedicated to helping people with type 2 diabetes manage their disease by developing and commercializing simple drug delivery devices that can be easily integrated into daily life.
The company's lead product, PAQ, is a wearable insulin delivery device that delivers both basal and bolus insulin for 3 days at a time. Its simple, discreet design enables people to easily experience the benefits of intensive insulin therapy, while remaining free from the burdens of daily insulin injections.
CeQur SA was established in January 2008 by Jim Peterson who saw the need to improve the quality of life for people with diabetes and who has a long history of working with the Joslin Diabetes Center and the diabetes community. As founder, Jim led CeQur from a spinout from Danfoss A/S, a global Danish industrial products group that developed the initial concept of the CeQur technology, and held the position of CEO until early 2014.
CeQur has completed clinical studies evaluating PAQ among people with type 2 diabetes with positive results. The company has advanced the technology to a commercial product obtaining a CE mark for PAQ in 2012.
CeQur is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.